Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1996-7-18
|
pubmed:abstractText |
A series of prolineboronic acid (boroPro) containing dipeptides were synthesized and assayed for their ability to inhibit the serine protease dipeptidyl peptidase IV (DPPIV). Inhibitory activity, which requires the (R)-stereoisomer of boroPro in the P1 position, appears to tolerate a variety of L-amino acids in the P2 position. Substitution at the P2 position which is not tolerated include the D-amino acids, alpha,alpha-disubstituted amino acids, and glycine. Specificity against DPPII and proline specific endopeptidase is reported. A correlation between the ability to inhibit DPPIV in cell culture and in the human mixed lymphocyte reaction is demonstrated. A synthesis of prolineboronic acid is reported as well as conditions for generating the fully unprotected boronic acid dipeptides in either their cyclic or acyclic forms.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0022-2623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2087-94
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:8642568-Boronic Acids,
pubmed-meshheading:8642568-Dipeptidyl-Peptidases and Tripeptidyl-Peptidases,
pubmed-meshheading:8642568-Enzyme Inhibitors,
pubmed-meshheading:8642568-Humans,
pubmed-meshheading:8642568-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:8642568-Magnetic Resonance Spectroscopy,
pubmed-meshheading:8642568-Mass Spectrometry,
pubmed-meshheading:8642568-Stereoisomerism,
pubmed-meshheading:8642568-Structure-Activity Relationship
|
pubmed:year |
1996
|
pubmed:articleTitle |
Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides.
|
pubmed:affiliation |
Research and Development Center, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, USA.
|
pubmed:publicationType |
Journal Article
|